U.S. CAR-T Cell Therapy Market Size, Share By Drug Type (Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others), By Indication (Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others), By End-Users (Hospitals, Cancer Research Centers, and Others) - Trends, Analysis and Forecast till 2034

Report Code: PMI542024 | Publish Date: July 2024 | No. of Pages: 154

Us Car T Cell Therapy Market Overview

U.S. CAR-T Cell Therapy Market was valued at USD 1.85 Billion in 2024 and is s expected to reach USD 10.3 Billion by 2034 growing at a CAGR of 3.8%

The CAR-T cell therapy market in the USA is a leading segment globally, characterized by cutting-edge research, substantial funding, and a high demand for advanced cancer treatments. The USA is at the forefront of CAR-T cell therapy development, with numerous breakthroughs and successful commercialization efforts marking its progress.

Us Car T Cell Therapy Market Dynamics

Key Drivers of Target Market:

Innovative Research and Development

The USA is a hub for innovative research and development in the field of CAR-T cell therapy. Renowned research institutions, biotech companies, and academic centers are continuously working on advancing CAR-T technologies and developing new therapies. The availability of substantial funding from both government and private sources supports extensive R&D activities, driving the growth of the CAR-T cell therapy market. This focus on innovation ensures that the USA remains a leader in developing next-generation cancer treatments.

High Prevalence of Cancer and Advanced Healthcare System

The high prevalence of various types of cancer in the USA creates a significant demand for effective treatment options. CAR-T cell therapy offers a promising alternative for patients who have not responded to traditional treatments. The advanced healthcare system in the USA is well-equipped to deliver these complex therapies, with specialized treatment centers and skilled medical professionals facilitating patient access to CAR-T cell treatments. This combination of high cancer incidence and advanced healthcare infrastructure drives the adoption and growth of CAR-T cell therapy in the USA. Additionally, the USA has a strong tradition of medical innovation and entrepreneurship, with a highly competitive market that fosters the development and commercialization of novel therapies.

Restrains:

Regulatory Hurdles and Approval Processes

While the USA has a robust regulatory framework, the stringent approval processes for new CAR-T therapies can be time-consuming and costly. Navigating these regulatory hurdles requires significant resources and expertise, which can delay the introduction of new treatments to the market. Additionally, the evolving nature of regulations concerning personalized medicine and advanced therapies adds another layer of complexity. These regulatory challenges can act as a barrier to the rapid expansion of the CAR-T cell therapy market in the USA, necessitating ongoing efforts to streamline approval processes and ensure regulatory clarity. Despite these challenges, the FDA has implemented expedited pathways such as the Breakthrough Therapy Designation and Priority Review to accelerate the development and approval of promising CAR-T cell therapies. However, ensuring patient safety and efficacy remain paramount, and striking the right balance between speed and thoroughness is crucial for advancing the field while maintaining regulatory standards.

Us Car T Cell Therapy Market Segmentation

The market is segmented based on Drug Type, Indication, and End-User.

U.S. CAR-T Cell Therapy Market Report Scope:

Attribute

Details

Market Size 2024

USD 1.85 Billion

Projected Market Size 2034

USD 10.3 Billion

CAGR Growth Rate

3.8%

Base year for estimation

2023

Forecast period

2024 – 2034

Market representation

Revenue in USD Billion & CAGR from 2024 to 2034

Market Segmentation

By Drug Type - Ciloleucel, Axicabtagene, Brexucabtagene Autoleucel, Tisagenlecleucel, and Others

By Indication - Acute Lymphocyctic Leukemia, Lymphoma, Non-Hodgkin Leukemia and Others

By End User - Hospitals, Cancer Research Centers, and Others

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2023 to 2034. For the purpose of this study, has segmented the U.S. CAR-T Cell Therapy Market report based on Drug Type, Indication, End User and Country:

Segmentation:

By Drug Type:

  • Ciloleucel
  • Axicabtagene
  • Brexucabtagene Autoleucel
  • Tisagenlecleucel
  • Others    

By Indication:

  • Acute Lymphocyctic Leukemia
  • Lymphoma
  • Non-Hodgkin Leukemia
  • Others

By End User:

  • Hospitals
  • Cancer Research Centers
  • Others

Us Car T Cell Therapy Market Key Players

The key players operating the U.S. CAR-T cell therapy market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, Sorrento Therapeutics Inc.

Us Car T Cell Therapy Market Company Profile

  • Bristol Myer Squibb, Inc. *
    • Company Overview
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Business Strategies
  • MERCK & CO. INC.
  • PFIZER INC.
  • Bluebird Bio-Inc.
  • Novartis AG
  • Caribou Biosciences Inc.
  • CELGENE CORPORATION, INC.
  • Sorrento Therapeutics Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Us Car T Cell Therapy Market Table of Contents

Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

Market Preview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By End User
    • Market Snippet, By Country
  • Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Market Trends
  • Product Launch
  • Merger and Acquisitions
  • Impact Analysis
  • PEST Analysis
  • Porter’s Analysis

Market Segmentation, By Drug Type, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Ciloleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Axicabtagene
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%),Forecast Period up to 10 Years
  • Brexucabtagene Autoleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Tisagenlecleucel
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Indication, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Acute Lymphocyctic Leukemia
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Lymphoma
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Non-Hodgkin Leukemia
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

  • Others
    • Overview

Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, End User, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Segment Trends
  • Hospitals
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Cancer Research Centers
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Others
    • Overview
    • Market Size and Forecast (USD Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, By Country, Forecast Period up to 10 Years, (USD Bn)

  • Overview
    • Market Value and Forecast (USD Bn), and Share Analysis (%), Forecast Period up to 10 Years
    • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
    • Country Trends

Competitive Landscape

  • Heat Map Analysis
  • Company Profiles
    • Bristol Myer Squibb
    • MERCK & CO. INC.
    • PFIZER INC.
    • Bluebird Bio-Inc.
    • Novartis AG
    • Caribou Biosciences Inc.
    • CELGENE CORPORATION, Inc.
    • Sorrento Therapeutics Inc.

The Last Word

  • Future Impact
  • About Us
  • Contact

FAQs

The U.S. CAR-T Cell Therapy Market is segmented into Drug Type, Indication, and End User.

Innovative Research and Development and High Prevalence of Cancer and Advanced Healthcare System.

The key players operating the U.S. CAR-T Cell Therapy Market includes, Bristol Myer Squibb, MERCK & CO. INC., PFIZER INC., Bluebird Bio-Inc., Novartis AG, Caribou Biosciences Inc., CELGENE CORPORATION, INC., Sorrento Therapeutics Inc.